Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Jan;39(1):52-7.
doi: 10.1016/j.leukres.2014.10.004. Epub 2014 Oct 30.

Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score

Jose Falantes  1 , Regina García Delgado  2 , Cristina Calderón-Cabrera  3 , Francisco J Márquez-Malaver  3 , David Valcarcel  4 , Dunia de Miguel  5 , Alicia Bailén  6 , Joan Bargay  7 , Teresa Bernal  8 , Jose R González-Porras  9 , Mar Tormo  10 , Fernando Ramos  11 , Rafael Andreu  12 , Blanca Xicoy  13 , Benet Nomdedeu  14 , Salut Brunet  15 , Joaquín Sánchez  16 , Antonio Fernández Jurado  17 , Santiago Bonanad  18 , Jose Antonio Pérez-Simón  3 , Guillermo Sanz  19 ; Spanish Group of Myelodysplastic Syndromes (GESMD)
Affiliations
Clinical Trial

Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score

Jose Falantes et al. Leuk Res. 2015 Jan.

Abstract

Scoring systems for lower-risk myelodysplastic syndrome (LR-MDS) recognize patients with a poorer than expected outcome. This study retrospectively analyzes the role of azacitidine in LR-MDS with adverse risk score and compared to an historical cohort treated with best supportive care or erythropoiesis-stimulating agents. Overall response to AZA was 40%. One and 2-year probabilities of survival were 62% and 45% for AZA vs. 25% and 11% (P=10(-4)). In a multivariable time-dependent analysis, response to AZA (CR/PR/HI) was associated with an improved survival (HR=0.234, 95% CI, 0.063-0.0863; P=0.029). Thrombocytopenia (<50 × 10(9)L(-1)) is confirmed as an adverse parameter in LR-MDS (HR=1.649, 95% CI, 1.012-2.687; P=0.045).

Keywords: Azacitidine; Lower-risk myelodysplastic syndrome; Outcome.

PubMed Disclaimer

Substances